Enliven Therapeutics (ELVN) director exercises options, sells 158,795 shares

Q: What insider activity did Enliven Therapeutics (ELVN) report for Mika K. Derynck?

Director Mika K. Derynck exercised stock options for 158,795 Enliven shares and sold 158,795 common shares. The transactions occurred on August 4, 2026 and involved both option exercises and an open-market sale reported on this Form 4.

Q: How many Enliven Therapeutics (ELVN) shares did the director sell and at what price?

Mika K. Derynck sold 158,795 shares of Enliven common stock at a weighted average price of $60.2134 per share. The sale was executed in multiple trades within a price range from $60.00 to $60.58 , according to the filing footnote.

Q: Were the Enliven Therapeutics (ELVN) stock options fully vested at exercise?

All options exercised in this Form 4 were fully vested and exercisable as of the transaction date. A footnote specifies that all shares subject to the reported options were fully vested and exercisable when the options were exercised.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Enliven Therapeutics, Inc. director Mika K. Derynck exercised stock options covering 158,795 shares of common stock on August 4, 2026 at exercise prices of $2.4800, $14.8500, $22.4700 and $25.2800 per share.

He then sold 158,795 shares at a weighted average price of $60.2134 per share, in multiple trades between $60.00 and $60.58, pursuant to a Rule 10b5-1 trading plan adopted on April 8, 2025. All options exercised were fully vested and exercisable.

Insider Trade Summary 10b5-1

Exercise and Sale: 158,795 shares ($7.84M approx. pre-tax spread)

Exercise and Sale 9 txns

Insider Derynck Mika K

Role Director

Sold 158,795 shs ($9.56M)

Approx. gross sale proceeds $9.56M

Approx. exercise cost $1.72M

Approx. pre-tax spread $7.84M

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) ^{F1, F3}	87,373	$0.00	$0.00
Exercise	Stock Option (right to buy) ^{F1, F3}	27,567	$0.00	$0.00
Exercise	Stock Option (right to buy) ^{F1, F3}	23,364	$0.00	$0.00
Exercise	Stock Option (right to buy) ^{F1, F3}	20,491	$0.00	$0.00
Exercise	Common Stock ^F1	87,373	$2.48	$217K
Exercise	Common Stock ^F1	27,567	$25.28	$697K
Exercise	Common Stock ^F1	23,364	$14.85	$347K
Exercise	Common Stock ^F1	20,491	$22.47	$460K
Sale	Common Stock ^{F1, F2}	158,795	$60.2134	$9.56M

Holdings After Transaction: Stock Option (right to buy) — 0 shares (Direct); Common Stock — 0 shares (Direct)

Footnotes (3)

F1. The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025.
F2. This transaction was executed in multiple trades at prices ranging from $60.00 to $60.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3. All of the shares subject to this option are fully vested and exercisable as of the date hereof.

Key Figures

Shares sold: 158,795 shares Weighted average sale price: $60.2134 per share Shares underlying options exercised: 158,795 shares +3 more

6 metrics

Shares sold 158,795 shares Common stock sale on 2026-08-04

Weighted average sale price $60.2134 per share Common stock sold in multiple trades between $60.00 and $60.58

Shares underlying options exercised 158,795 shares Total derivative exercises on 2026-08-04

Option exercise price $2.4800 per share Stock option expiring 2031-08-01

Option exercise price $25.2800 per share Stock option expiring 2033-02-23

Option exercise price $14.8500 per share Stock option expiring 2034-02-13

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, Stock Option (right to buy), fully vested and exercisable

4 terms

Rule 10b5-1 trading plan regulatory

"The option exercises and sales were effected pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported above reflects the weighted average sale price"

Stock Option (right to buy) financial

"Stock Option (right to buy) reported as a derivative security"

fully vested and exercisable financial

"All of the shares subject to this option are fully vested and exercisable"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/06/2026 - 08:18 PM Accepted by SEC EDGAR 08/06/2026 - 08:18 PM

FAQ

What insider activity did Enliven Therapeutics (ELVN) report for Mika K. Derynck?

Director Mika K. Derynck exercised stock options for 158,795 Enliven shares and sold 158,795 common shares. The transactions occurred on August 4, 2026 and involved both option exercises and an open-market sale reported on this Form 4.

At what prices were the Enliven Therapeutics (ELVN) stock options exercised?

The reported stock options were exercised at strike prices of $2.4800, $14.8500, $22.4700 and $25.2800 per share. These options were described as fully vested and exercisable as of the transaction date, with expirations ranging from 2031 to 2035.

How many Enliven Therapeutics (ELVN) shares did the director sell and at what price?

Mika K. Derynck sold 158,795 shares of Enliven common stock at a weighted average price of $60.2134 per share. The sale was executed in multiple trades within a price range from $60.00 to $60.58, according to the filing footnote.

Were the Enliven Therapeutics (ELVN) insider transactions under a Rule 10b5-1 plan?

Yes. The option exercises and related sales were effected under a Rule 10b5-1 trading plan adopted by the reporting person on April 8, 2025. The Form 4 also indicates the Rule 10b5-1 checkbox as affirmed for these transactions.

Were the Enliven Therapeutics (ELVN) stock options fully vested at exercise?

All options exercised in this Form 4 were fully vested and exercisable as of the transaction date. A footnote specifies that all shares subject to the reported options were fully vested and exercisable when the options were exercised.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Derynck Mika K

(Last)

(First)

(Middle)

C/O ENLIVEN THERAPEUTICS, INC.

205 PARK ROAD

(Street)

BURLINGAME

CALIFORNIA

94010

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/04/2026		M⁽¹⁾		87,373	A	$2.48	87,373	D
Common Stock	08/04/2026		M⁽¹⁾		27,567	A	$25.28	114,940	D
Common Stock	08/04/2026		M⁽¹⁾		23,364	A	$14.85	138,304	D
Common Stock	08/04/2026		M⁽¹⁾		20,491	A	$22.47	158,795	D
Common Stock	08/04/2026		S⁽¹⁾		158,795	D	$60.2134⁽²⁾	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$2.48	08/04/2026		M⁽¹⁾			87,373	⁽³⁾	08/01/2031	Common Stock	87,373	$0	0	D
Stock Option (right to buy)	$25.28	08/04/2026		M⁽¹⁾			27,567	⁽³⁾	02/23/2033	Common Stock	27,567	$0	0	D
Stock Option (right to buy)	$14.85	08/04/2026		M⁽¹⁾			23,364	⁽³⁾	02/13/2034	Common Stock	23,364	$0	0	D
Stock Option (right to buy)	$22.47	08/04/2026		M⁽¹⁾			20,491	⁽³⁾	02/06/2035	Common Stock	20,491	$0	0	D

Explanation of Responses:

1. The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025.

2. This transaction was executed in multiple trades at prices ranging from $60.00 to $60.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. All of the shares subject to this option are fully vested and exercisable as of the date hereof.

	/s/ Ben Hohl, by power of attorney	08/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR